NCT02323022View on ClinicalTrials.gov

Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)

PHASE3CompletedINTERVENTIONAL
Enrollment

618

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

March 31, 2020

Study Completion Date

January 31, 2022

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

IAC regimen

Induction treatment for initially diagnosed AML with IAC regimen, including Cladribine 5mg/msq/d (d1-5), Ara-C 100mg/msq/d(d1-7) and IDA 8mg/msq/d (d1-3)

DRUG

IA regimen

Induction treatment for initially diagnosed AML with IAC regimen, including Ara-C 100mg/msq/d (d1-7) and IDA 12mg/msq/d (d1-3)

Trial Locations (1)

215006

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Soochow University

OTHER

NCT02323022 - Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML) | Biotech Hunter | Biotech Hunter